Dossier
kidney transplant infections
Coverage of kidney transplant infections in the Nexus archive.
- Ipsen is acquiring a Swiss biotech for up to $800 million to treat kidney transplant infections
Ipsen, a French drugmaker, is acquiring Swiss biotech Memo for up to $800 million. The upfront payment is 200 million euros, targeting a kidney transplant infection with no approved treatments.